NCT05581875 - A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 20, 2022

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions

Multiple MyelomaMultiple Myeloma in RelapseNeoplasmsGammopathy, MonoclonalParaproteinemiasBlood Protein DisordersHaematologic DiseaseCorneal DiseaseNeoplasms, Plasma Cell

Interventions

DRUG

Belantamab Mafodotin-Blmf

Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder. Blmf will be delivered as IV solution over at least 30 minutes

DRUG

Daratumumab

Daratumumab will be administered with subcutaneous injections. On days where Blmf is given together with daratumumab, daratumumab should be performed first.

DRUG

Pomalidomide

Pomalidomide will be administered per os.

DRUG

Dexamethasone

Dexamethasone will be administered intravenously or per os.